When nutrition interacts with osteoblast function: Molecular mechanisms of polyphenols

Nutrition Research Reviews

Volumn 22, Issue 1, 2009, Pages 68-81

  Trzeciakiewicz, Anna ^a   Habauzit, Véronique ^a   Horcajada, Marie Nölle ^a  

^a INRA and University of Auvergne   (France)

Author keywords

Bone metabolism; Osteoblasts; Polyphenols; Signalling

Indexed keywords

BONE MORPHOGENETIC PROTEIN; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; POLYPHENOL; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; FLAVONOID; PHENOL DERIVATIVE; POLYPHENOLS; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

BONE MASS; CELL FUNCTION; CELL METABOLISM; FOOD INTAKE; NUTRITION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PROTEIN EXPRESSION; REVIEW; CHEMICAL STRUCTURE; CHEMISTRY; DIET; DRUG EFFECT; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

DIET; FLAVONOIDS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR STRUCTURE; OSTEOBLASTS; PHENOLS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 69249209977     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S095442240926402X     Document Type: Review

References (122)

1. Pettifor JM, Prentice A & Cleaton-Jones P (2003) The skeletal system. In Nutrition and Metabolism, pp. 247-283 [MJ Gibney, IA Macdonald and HM Roche, editors]. Oxford: Blackwell Publishing.
2. Sommerfeldt DW & Rubin CT (2001) Biology of bone and how it orchestrates the form and function of the skeleton. Eur Spine J 10, Suppl. 2, S86-S95.
3. Simon LS (2005) Osteoporosis. Clin Geriatr Med 21, 603-629, viii.
4. Suzuki A, Sekiguchi S, Asano S, et al. (2008) Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis. J Pharmacol Sci 106, 530-535. (Pubitemid 351556228)
5. Mundy GR (2006) Nutritional modulators of bone remodeling during aging. Am J Clin Nutr 83, S427-S430.
6. New SA (1999) Bone health: the role of micronutrients. Br Med Bull 55, 619-633.
7. Ilich JZ & Kerstetter JE (2000) Nutrition in bone health revisited: a story beyond calcium. J Am Coll Nutr 19, 715-737.
8. Heaney RP (2007) Bone health. Am J Clin Nutr 85, 300S-303S.
9. Habauzit V & Horcajada MN (2008) Phenolic phytochemicals and bone. Phytochem Rev 7, 313-344.
10. Marie PJ (2008) Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 473, 98-105.
11. Bringhurst FR, Demay MB, Krane SM, et al. (2005) Bone and mineral metabolism in health and disease. In Harrison's Principles of Internal Medicine, pp. 2238-2249 [DL Kasper, E Braunwald and AS Fauci, editors]. New York: McGraw-Hill.
12. Katagiri T & Takahashi N (2002) Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8, 147-159. (Pubitemid 34535063)
13. Strewler GJ (2001) Local and systemic control of the osteoblast. J Clin Invest 107, 271-272.
14. Baylink DJ, Finkelman RD & Mohan S (1993) Growth factors to stimulate bone formation. J Bone Miner Res 8, Suppl. 2, S565-S572. (Pubitemid 24015250)
15. Kalajzic I, Staal A, Yang WP, et al. (2005) Expression profile of osteoblast lineage at defined stages of differentiation. J Biol Chem 280, 24618-24626. (Pubitemid 40934550)
16. Yamaguchi A, Komori T & Suda T (2000) Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 21, 393-411. (Pubitemid 32275586)
17. Westendorf JJ, Kahler RA & Schroeder TM (2004) Wnt signaling in osteoblasts and bone diseases. Gene 341, 19-39. (Pubitemid 39335880)
18. Niu TH & Rosen CJ (2005) The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene 361, 38-56. (Pubitemid 41506932)
19. Huang W, Yang S, Shao J, et al. (2007) Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 12, 3068-3092.
20. Stein GS & Lian JB (1993) Molecular mechanisms mediating proliferation differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14, 424-442.
21. Ehrlich PJ & Lanyon LE (2002) Mechanical strain and bone cell function: a review. Osteoporos Int 13, 688-700.
22. Burger EH, Klein-Nulend J & Smit TH (2003) Strain-derived canalicular fluid flow regulates osteoclast activity in a remodelling osteon - a proposal. J Biomech 36, 1453-1459. (Pubitemid 37117352)
23. Ash P, Loutit JF & Townsend KM (1980) Osteoclasts derived from haematopoietic stem cells. Nature 283, 669-670. (Pubitemid 10099996)
24. Felix R, Cecchini MG & Fleisch H (1990) Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 127, 2592-2594. (Pubitemid 20381799)
25. Kodama H, Yamasaki A, Nose M, et al. (1991) Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J Exp Med 173, 269-272.
26. Kodama H, Nose M, Niida S, et al. (1991) Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 173, 1291-1294.
27. Sambrook P & Cooper C (2006) Osteoporosis. Lancet 367, 2010-2018.
28. Scalbert A, Manach C, Morand C, et al. (2005) Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 45, 287-306.
29. Manach C, Williamson G, Morand C, et al. (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81, 230S-242S.
30. Kroon PA, Clifford MN, Crozier A, et al. (2004) How should we assess the effects of exposure to dietary polyphenols in vitro? Am J Clin Nutr 80, 15-21.
31. Manach C, Scalbert A, Morand C, et al. (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79, 727-747.
32. Williamson G, Barron D, Shimoi K, et al. (2005) In vitro biological properties of flavonoid conjugates found in vivo. Free Radic Res 39, 457-469.
33. Serra H, Mendes T, Bronze MR, et al. (2008) Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem 16, 4009-4018.
34. O'Leary KA, Day AJ, Needs PW, et al. (2001) Flavonoid glucuronides are substrates for human liver β-glucuronidase. FEBS Lett 503, 103-106.
35. Khlebnikov AI, Schepetkin IA, Domina NG, et al. (2007) Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems. Bioorg Med Chem 15, 1749-1770.
36. Loke WM, Proudfoot JM, McKinley AJ, et al. (2008) Quercetin and its in vivo metabolites inhibit neutrophil-mediated low-density lipoprotein oxidation. J Agric Food Chem 56, 3609-3615.
37. Tribolo S, Lodib F, Connor C, et al. (2008) Comparative effects of quercetin and its predominant human metabolites on adhesion molecule expression in activated human vascular endothelial cells. Atherosclerosis 197, 50-56. (Pubitemid 351273272)
38. Suri S, Taylor MA, Verity A, et al. (2008) A comparative study of the effects of quercetin and its glucuronide and sulfate metabolites on human neutrophil function in vitro. Biochem Pharmacol 76, 645-653.
39. Schroeter H, Boyd C, Spencer JP, et al. (2002) MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol Aging 23, 861-880. (Pubitemid 35217712)
40. Williams RJ, Spencer JP & Rice-Evans C (2004) Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med 36, 838-849.
41. Spinozzi F, Pagliacci MC, Migliorati G, et al. (1994) The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 18, 431-439. (Pubitemid 24169825)
42. Yamaguchi M (2002) Isoflavone and bone metabolism: its cellular mechanism and preventive role in bone loss. J Health Sci 48, 209-222.
43. Sugimoto E & Yamaguchi M (2000) Stimulatory effect of daidzein in osteoblastic MC3T3-E1 cells. Biochem Pharmacol 59, 471-475. (Pubitemid 30045585)
44. Orzechowski A, Ostaszewski P, Jank M, et al. (2002) Bioactive substances of plant origin in food - impact on genomics. Reprod Nutr Dev 42, 461-477. (Pubitemid 36113385)
45. Katiyar SK, Afaq F, Azizuddin K, et al. (2001) Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol (2)-epigallocatechin-3-gallate. Toxicol Appl Pharmacol 176, 110-117. (Pubitemid 33015861)
46. Balasubramanian S, Efimova T & Eckert RL (2002) Green tea polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes. J Biol Chem 277, 1828-1836. (Pubitemid 34968756)
47. Bradamante S, Barenghi L & Villa A (2004) Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22, 169-188.
48. Aziz MH, Kumar R & Ahmad N (2003) Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 23, 17-28.
49. King RE, Bomser JA & Min DB (2006) Bioactivity of resveratrol. Compr Rev Food Sci Food Safety 5, 65-70.
50. Das S, Tosaki A, Bagchi D, et al. (2006) Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen-and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther 317, 980-988. (Pubitemid 43764100)
51. Linder MW, Falkner KC, Srinivasan G, et al. (1999) Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. Drug Metab Rev 31, 247-271. (Pubitemid 29106661)
52. Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29, 2905-2919. (Pubitemid 32685217)
53. Kuiper GG, Lemmen JG, Carlsson B, et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor b. Endocrinology 139, 4252-4263. (Pubitemid 28513713)
54. Bennetau-Pelissero C, Latonnelle K, Sequeira A, et al. (2000) Phytoestrogens, endocrine disrupters from food. Analusis 28, 763-775.
55. Niehrs C & Meinhardt H (2002) Developmental biology - modular feedback. Nature 417, 35-36.
56. Noe V, Penuelas S, Lamuela-Raventos RM, et al. (2004) Epicatechin and a cocoa polyphenolic extract modulate gene expression in human Caco-2 cells. J Nutr 134, 2509-2516. (Pubitemid 39315247)
57. Ko CH, Shen SC, Lin HY, et al. (2002) Flavanones structure-related inhibition on TPA-induced tumor promotion through suppression of extracellular signal-regulated protein kinases: involvement of prostaglandin E-2 in anti-promotive process. J Cell Physiol 193, 93-102.
58. Yang CS, Lambert JD, Hou Z, et al. (2006) Molecular targets for the cancer preventive activity of tea polyphenols. Mol Carcinog 45, 431-435. (Pubitemid 43865851)
59. O'Prey J, Brown J, Fleming J, et al. (2003) Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. Biochem Pharmacol 66, 2075-2088. (Pubitemid 37377853)
60. Vittal R, Selvanayagam ZE, Sun Y, et al. (2004) Gene expression changes induced by green tea polyphenol (2)- epigallocatechin-3-gallate in human bronchial epithelial 21BES cells analyzed by DNA microarray. Mol Cancer Ther 3, 1091-1099. (Pubitemid 39295006)
61. Muller M & Kersten S (2003) Nutrigenomics: goals and strategies. Nat Rev Genet 4, 315-322.
62. Komori T (2005) Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem 95, 445-453. (Pubitemid 41420175)
63. Celil AB, Hollinger JO & Campbell PG (2005) Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling. J Cell Biochem 95, 518-528.
64. Ducy P (2000) Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 219, 461-471.
65. Nakashima K, Zhou X, Kunkel G, et al. (2002) The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. Cell 108, 17-29. (Pubitemid 34137009)
66. Lee MH, Kwon TG, Park HS, et al. (2003) BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem Biophys Res Commun 309, 689-694.
67. Chen CH, Ho ML, Chang JK, et al. (2005) Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. Osteoporos Int 16, 2039-2045.
68. Vali B, Rao LG & El-Sohemy A (2007) Epigallocatechin-3- gallate increases the formation of mineralized bone nodules by human osteoblast-like cells. J Nutr Biochem 18, 341-347. (Pubitemid 46613954)
69. De Wilde A, Lieberherr M, Colin C, et al. (2004) A low dose of daidzein acts as an ERb-selective agonist in trabecular osteoblasts of young female piglets. J Cell Physiol 200, 253-262. (Pubitemid 38885706)
70. Mizutani K, Ikeda K, Kawai Y, et al. (1998) Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 253, 859-863. (Pubitemid 29039235)
71. Dai Z, Li Y, Quarles LD, et al. (2007) Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 14, 806-814. (Pubitemid 350017876)
72. Liu M, Liu HP, Lu XM, et al. (2007) Simultaneous determination of icariin, icariside II and osthole in rat plasma after oral administration of the extract of Gushudan (a Chinese compound formulation) by LC-MS/MS. J Chromatogr B 860, 113-120. (Pubitemid 350161468)
73. Zhao J, Ohba S, Shinkai M, et al. (2008) Icariin induces osteogenic differentiation in vitro in a BMP- and Runx2- dependent manner. Biochem Biophys Res Commun 369, 444-448.
74. Pinkus R, Weiner LM & Daniel V (1996) Role of oxidants and antioxidants in the induction of AP-1, NF-κ B, and glutathione S-transferase gene expression. J Biol Chem 271, 13422-13429. (Pubitemid 26185383)
75. Fujioka S, Niu JG, Schmidt C, et al. (2004) NF-KB and AP- 1 connection: mechanism of NF-κB-dependent regulation of AP-1 activity. Mol Cell Biol 24, 7806-7819. (Pubitemid 39121503)
76. Wagner EF (2002) Functions of AP1 (Fos/Jun) in bone development. Ann Rheum Dis 61, Suppl. 2, ii40-ii42.
77. McCabe LR, Kockx M, Lian J, et al. (1995) Selective expression of fos- and jun-related genes during osteoblast proliferation and differentiation. Exp Cell Res 218, 255-262.
78. Frigo DE, Duong BN, Melnik LI, et al. (2002) Flavonoid phytochemicals regulate activator protein-1 signal transduction pathways in endometrial and kidney stable cell lines. J Nutr 132, 1848-1853.
79. Pang JL, Ricupero DA, Huang S, et al. (2006) Differential activity of kaempferol and quercetin in attenuating tumor necrosis factor receptor family signaling in bone cells. Biochem Pharmacol 71, 818-826. (Pubitemid 43208838)
80. Son YO, Kook SH, Choi KC, et al. (2008) Quercetin accelerates TNF-α-induced apoptosis of MC3T3-E1 osteoblastic cells through caspase-dependent and JNK-mediated pathways. Eur J Pharmacol 579, 26-33.
81. Lee SU, Shin HK, Min YK, et al. (2008) Emodin accelerates osteoblast differentiation through phosphatidylinositol 3-kinase activation and bone morphogenetic protein-2 gene expression. Int Immunopharmacol 8, 741-747.
82. Tokuda H, Takai S, Matsushima-Nishiwaki R, et al. (2007) (-)-Epigallocatechin gallate enhances prostaglandin F2α-induced VEGF synthesis via upregulating SAPK/JNK activation in osteoblasts. J Cell Biochem 100, 1146-1153. (Pubitemid 46480397)
83. Canalis E, Economides AN & Gazzerro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24, 218-235. (Pubitemid 36515285)
84. Yamashita T, Ishii H, Shimoda K, et al. (1996) Subcloning of three osteoblastic cell lines with distinct differentiation phenotypes from the mouse osteoblastic cell line KS-4. Bone 19, 429-436. (Pubitemid 126745120)
85. Miyazono K, Maeda S & Imamura T (2005) BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16, 251-263. (Pubitemid 40910315)
86. Shi Y & Massague J (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700. (Pubitemid 36724933)
87. Boden SD, Kang J, Sandhu H, et al. (2002) Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 27, 2662-2673. (Pubitemid 35425320)
88. Zimmerman LB, De Jesús-Escobar JM & Harland RM (1996) The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86, 599-606.
89. Groppe J, Greenwald J, Wiater E, et al. (2002) Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420, 636-642. (Pubitemid 36764490)
90. Gazzerro E, Gangji V & Canalis E (1998) Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 102, 2106-2114. (Pubitemid 29018817)
91. Kuo P-L, Hsu Y-L, Chang C-H, et al. (2005) Ostholemediated cell differentiation through bone morphogenetic protein-2/p38 and extracellular signal-regulated kinase 1/2 pathway in human osteoblast cells. J Pharmacol Exp Ther 314, 1290-1299.
92. Tang CH, Yang RS, Chien MY, et al. (2008) Enhancement of bone morphogenetic protein-2 expression and bone formation by coumarin derivatives via p38 and ERK-dependent pathway in osteoblasts. Eur J Pharmacol 579, 40-49.
93. Chang JK, Hsu YL, Teng IC, et al. (2006) Piceatannol stimulates osteoblast differentiation that may be mediated by increased bone morphogenetic protein-2 production. Eur J Pharmacol 551, 1-9.
94. Su JL, Yang CY, Zhao M, et al. (2007) Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem 282, 19385-19398. (Pubitemid 47100112)
95. Hsu YL, Chang JK, Tsai CH, et al. (2007) Myricetin induces human osteoblast differentiation through bone morphogenetic protein-2/p38 mitogen-activated protein kinase pathway. Biochem Pharmacol 73, 504-514.
96. Wolter F, Clausnitzer A, Akoglu B, et al. (2002) Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr 132, 298-302. (Pubitemid 34135611)
97. Yanez J, Vicente V, Alcaraz M, et al. (2004) Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer 49, 191-199. (Pubitemid 39487879)
98. Kousteni S, Bellido T, Plotkin LI, et al. (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719-730. (Pubitemid 32241022)
99. Kousteni S, Han L, Chen JR, et al. (2003) Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111, 1651-1664. (Pubitemid 38057747)
100. Manolagas SC, Kousteni S & Jilka RL (2002) Sex steroids and bone. Recent Prog Horm Res 57, 385-409.
101. Ascenzi P, Bocedi A & Maria M (2006) Structure-function relationship of estrogen receptor a and b: impact on human health. Mol Aspect Med 27, 299-402. (Pubitemid 44255847)
102. Nilsson S, Makela S, Treuter E, et al. (2001) Mechanisms of estrogen action. Physiol Rev 81, 1535-1565.
103. Losel RM, Falkenstein E, Feuring M, et al. (2003) Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83, 965-1016. (Pubitemid 36828929)
104. Watson CS, Bulayeva NN, Wozniak AL, et al. (2005) Signaling from the membrane via membrane estrogen receptor-α estrogens, xenoestrogens, and phytoestrogens. Steroids 70, 364-371. (Pubitemid 40616034)
105. Prouillet C, Maziere JC, Maziere C, et al. (2004) Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem Pharmacol 67, 1307-1313. (Pubitemid 38315096)
106. Kousteni S, Chen JR, Bellido T, et al. (2002) Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298, 843-846. (Pubitemid 35231540)
107. Dai Z, Li Y, Quarles LD, et al. (2007) Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 14, 806-814. (Pubitemid 350017876)
108. Weitzmann MN & Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116, 1186-1194.
109. Kono SJ, Oshima Y, Hoshi K, et al. (2007) Erk pathways negatively regulate matrix mineralization. Bone 40, 68-74. (Pubitemid 44839341)
110. Driggers PH & Segars JH (2002) Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 13, 422-427.
111. Totta P, Acconcia F, Leone S, et al. (2004) Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor a and b signalling. IUBMB Life 56, 491-499. (Pubitemid 39582784)
112. Cassidy A & Dalais FS (2003) Phytochemicals. In Nutrition and Metabolism, pp. 307-317 [MJ Gibney, IA Macdonald and HM Roche, editors]. Oxford: Blackwell Publishing.
113. Chen XW, Garner SC & Anderson JJ (2002) Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. Biochem Biophys Res Commun 295, 417-422.
114. Clifford MN & Scalbert A (2000) Ellagitannins - nature, occurrence and dietary burden. J Sci Food Agric 80, 1118-1125. (Pubitemid 30319403)
115. Papoutsi Z, Kassi E, Tsiapara A, et al. (2005) Evaluation of estrogenic/antiestrogenic activity of ellagic acid via the estrogen receptor subtypes ERa and ERb. J Agric Food Chem 53, 7715-7720. (Pubitemid 41499614)
116. Simonet WS, Lacey DL, Dunstan CR, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319.
117. Rodan GA & Martin TJ (1981) Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif Tissue Int 33, 349-351.
118. Lacey DL, Timms E, Tan HL, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176. (Pubitemid 28180851)
119. Yasuda H, Shima N, Nakagawa N, et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95, 3597-3602. (Pubitemid 28173173)
120. Hsu H, Lacey DL, Dunstan CR, et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96, 3540-3545. (Pubitemid 29168945)
121. Bu SY, Hunt TS & Smith BJ (2009) Dried plum polyphenols attenuate the detrimental effects of TNF-α on osteoblast function coincident with up-regulation of Runx2, Osterix and IGF-I. J Nutr Biochem 20, 35-44.
122. University of Michigan (2005) Bone remodeling. http://www.umich.edu/news/ Releases/2005/Feb05/bone.html